- Home
- PCSA vs ASTI Comparison
PCSA vs ASTI Comparison
Compare PCSA & ASTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- ASTI
- Stock Information
- Founded
- PCSA 2011
- ASTI 2005
- Country
- PCSA United States
- ASTI United States
- Employees
- PCSA N/A
- ASTI N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- ASTI Semiconductors
- Sector
- PCSA Health Care
- ASTI Technology
- Exchange
- PCSA Nasdaq
- ASTI Nasdaq
- Market Cap
- PCSA 3.3M
- ASTI 2.9M
- IPO Year
- PCSA N/A
- ASTI N/A
- Fundamental
- Price
- PCSA $0.20
- ASTI $2.54
- Analyst Decision
- PCSA Strong Buy
- ASTI
- Analyst Count
- PCSA 1
- ASTI 0
- Target Price
- PCSA $2.00
- ASTI N/A
- AVG Volume (30 Days)
- PCSA 44.0M
- ASTI 6.6M
- Earning Date
- PCSA 08-12-2025
- ASTI 08-05-2025
- Dividend Yield
- PCSA N/A
- ASTI N/A
- EPS Growth
- PCSA N/A
- ASTI N/A
- EPS
- PCSA N/A
- ASTI N/A
- Revenue
- PCSA N/A
- ASTI $51,917.00
- Revenue This Year
- PCSA N/A
- ASTI N/A
- Revenue Next Year
- PCSA N/A
- ASTI N/A
- P/E Ratio
- PCSA N/A
- ASTI N/A
- Revenue Growth
- PCSA N/A
- ASTI N/A
- 52 Week Low
- PCSA $0.15
- ASTI $1.10
- 52 Week High
- PCSA $3.10
- ASTI $12.00
- Technical
- Relative Strength Index (RSI)
- PCSA 40.42
- ASTI 59.30
- Support Level
- PCSA $0.19
- ASTI $2.10
- Resistance Level
- PCSA $0.33
- ASTI $3.86
- Average True Range (ATR)
- PCSA 0.07
- ASTI 0.44
- MACD
- PCSA -0.01
- ASTI 0.08
- Stochastic Oscillator
- PCSA 1.67
- ASTI 52.17
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About ASTI Ascent Solar Technologies Inc.
Ascent Solar Technologies Inc is engaged in the manufacturing, and selling of photovoltaic products (PV) solar modules that are flexible, durable, and possess attractive power-to-weight and power-to-area performance. The company is integrating its PV products into scalable and high-value markets such as agrivoltaics, aerospace, satellites, near-earth orbiting vehicles, and fixed-wing unmanned aerial vehicles (UAV). Ascent is also working to expand its portable solar chargers, such as the XD-12. The company markets and sells its products through OEMs, system integrators, distributors, retailers, and e-commerce companies.